Introduction to section VIII: Management and outcome assessment

John Varga, Fredrick Wigley, Christopher P. Denton

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Scleroderma has complex pathogenesis, and its protean clinical and pathological manifestations reflect a disease process affecting multiple organs. In addition, scleroderma encompasses a series of related but distinct entities that are characterized by different course, severity, response to therapy, and outcomes. Scleroderma causes pain, disfigurement, functional impairment, and a substantial decrease in life expectancy. The survival of patients with scleroderma has shown improvement during the past two decades. This improvement in survival, as well as in disease-associated morbidity and disability, is due to advances in diagnosis and early recognition of internal organ involvement, as well as successful management of selected complications such as pulmonary arterial hypertension, Raynaud phenomenon, gastroesophageal reflux disease, ischemic digital ulcers, and scleroderma renal crisis. Additionally, recognition of prognostic risk factors, such as scleroderma-associated autoantibodies, has permitted better risk stratification, which is indispensible for both more effective clinical trials, as well for optimized patient management. Risk stratification in scleroderma enables the selection of more precise therapies targeted to the individual scleroderma patient while reducing potential drug toxicities.

Original languageEnglish (US)
Title of host publicationScleroderma: From Pathogenesis to Comprehensive Management
PublisherSpringer International Publishing
Pages565-566
Number of pages2
ISBN (Electronic)9783319314075
ISBN (Print)9783319314051
DOIs
StatePublished - Jan 1 2016

Fingerprint

Outcome Assessment (Health Care)
Raynaud Disease
Survival
Gastroesophageal Reflux
Life Expectancy
Drug-Related Side Effects and Adverse Reactions
Pulmonary Hypertension
Autoantibodies
Ulcer
Clinical Trials
Morbidity
Kidney
Pain
Therapeutics

Keywords

  • Classification
  • Clinical trials
  • Disease-modifying therapy
  • Integrated management
  • Multidisciplinary care
  • Risk stratification
  • Screening

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Varga, J., Wigley, F., & Denton, C. P. (2016). Introduction to section VIII: Management and outcome assessment. In Scleroderma: From Pathogenesis to Comprehensive Management (pp. 565-566). Springer International Publishing. https://doi.org/10.1007/978-3-319-31407-5_40

Introduction to section VIII : Management and outcome assessment. / Varga, John; Wigley, Fredrick; Denton, Christopher P.

Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing, 2016. p. 565-566.

Research output: Chapter in Book/Report/Conference proceedingChapter

Varga, J, Wigley, F & Denton, CP 2016, Introduction to section VIII: Management and outcome assessment. in Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing, pp. 565-566. https://doi.org/10.1007/978-3-319-31407-5_40
Varga J, Wigley F, Denton CP. Introduction to section VIII: Management and outcome assessment. In Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing. 2016. p. 565-566 https://doi.org/10.1007/978-3-319-31407-5_40
Varga, John ; Wigley, Fredrick ; Denton, Christopher P. / Introduction to section VIII : Management and outcome assessment. Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing, 2016. pp. 565-566
@inbook{6841e0394cee458ab4111aad2e2349a5,
title = "Introduction to section VIII: Management and outcome assessment",
abstract = "Scleroderma has complex pathogenesis, and its protean clinical and pathological manifestations reflect a disease process affecting multiple organs. In addition, scleroderma encompasses a series of related but distinct entities that are characterized by different course, severity, response to therapy, and outcomes. Scleroderma causes pain, disfigurement, functional impairment, and a substantial decrease in life expectancy. The survival of patients with scleroderma has shown improvement during the past two decades. This improvement in survival, as well as in disease-associated morbidity and disability, is due to advances in diagnosis and early recognition of internal organ involvement, as well as successful management of selected complications such as pulmonary arterial hypertension, Raynaud phenomenon, gastroesophageal reflux disease, ischemic digital ulcers, and scleroderma renal crisis. Additionally, recognition of prognostic risk factors, such as scleroderma-associated autoantibodies, has permitted better risk stratification, which is indispensible for both more effective clinical trials, as well for optimized patient management. Risk stratification in scleroderma enables the selection of more precise therapies targeted to the individual scleroderma patient while reducing potential drug toxicities.",
keywords = "Classification, Clinical trials, Disease-modifying therapy, Integrated management, Multidisciplinary care, Risk stratification, Screening",
author = "John Varga and Fredrick Wigley and Denton, {Christopher P.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-31407-5_40",
language = "English (US)",
isbn = "9783319314051",
pages = "565--566",
booktitle = "Scleroderma: From Pathogenesis to Comprehensive Management",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Introduction to section VIII

T2 - Management and outcome assessment

AU - Varga, John

AU - Wigley, Fredrick

AU - Denton, Christopher P.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Scleroderma has complex pathogenesis, and its protean clinical and pathological manifestations reflect a disease process affecting multiple organs. In addition, scleroderma encompasses a series of related but distinct entities that are characterized by different course, severity, response to therapy, and outcomes. Scleroderma causes pain, disfigurement, functional impairment, and a substantial decrease in life expectancy. The survival of patients with scleroderma has shown improvement during the past two decades. This improvement in survival, as well as in disease-associated morbidity and disability, is due to advances in diagnosis and early recognition of internal organ involvement, as well as successful management of selected complications such as pulmonary arterial hypertension, Raynaud phenomenon, gastroesophageal reflux disease, ischemic digital ulcers, and scleroderma renal crisis. Additionally, recognition of prognostic risk factors, such as scleroderma-associated autoantibodies, has permitted better risk stratification, which is indispensible for both more effective clinical trials, as well for optimized patient management. Risk stratification in scleroderma enables the selection of more precise therapies targeted to the individual scleroderma patient while reducing potential drug toxicities.

AB - Scleroderma has complex pathogenesis, and its protean clinical and pathological manifestations reflect a disease process affecting multiple organs. In addition, scleroderma encompasses a series of related but distinct entities that are characterized by different course, severity, response to therapy, and outcomes. Scleroderma causes pain, disfigurement, functional impairment, and a substantial decrease in life expectancy. The survival of patients with scleroderma has shown improvement during the past two decades. This improvement in survival, as well as in disease-associated morbidity and disability, is due to advances in diagnosis and early recognition of internal organ involvement, as well as successful management of selected complications such as pulmonary arterial hypertension, Raynaud phenomenon, gastroesophageal reflux disease, ischemic digital ulcers, and scleroderma renal crisis. Additionally, recognition of prognostic risk factors, such as scleroderma-associated autoantibodies, has permitted better risk stratification, which is indispensible for both more effective clinical trials, as well for optimized patient management. Risk stratification in scleroderma enables the selection of more precise therapies targeted to the individual scleroderma patient while reducing potential drug toxicities.

KW - Classification

KW - Clinical trials

KW - Disease-modifying therapy

KW - Integrated management

KW - Multidisciplinary care

KW - Risk stratification

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=85018911527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018911527&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-31407-5_40

DO - 10.1007/978-3-319-31407-5_40

M3 - Chapter

AN - SCOPUS:85018911527

SN - 9783319314051

SP - 565

EP - 566

BT - Scleroderma: From Pathogenesis to Comprehensive Management

PB - Springer International Publishing

ER -